SHORT HILLS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today preliminary results from a Phase I clinical trial of sapacitabine (CYC682), a novel orally available nucleoside analog. The results, presented as a poster at the 18th EORTC-NCI-AACR1 symposium on “Molecular Targets and Cancer Therapeutics” in Prague, Czech Republic, demonstrated that the compound could be safely administered to patients with refractory solid tumors or lymphomas and might be active in several tumor types. The trial is part of a Phase I program that included three additional Phase I studies: two in patients with incurable solid tumors and one in patients with advanced leukemias and myelodysplastic syndromes.
